YG1699 Has Completed Phase l Clinical Trial With 64 HealthySubjects

2020-02-10 00:00:00

SAD/ MAD/ FD experiments: All the experimental purposes were successfully achieved

- No case of SAE, at least 20 times of the treatment window


·There was no significant effect of high-fat food on PK exposure, and there was no drug accumulation after repeatedadministration

. Significant pharmacodynamic PD markers were observed. Significantly increased GLP-1/PYY

. Significantly reduce postprandial blood glucose